González Vázquez Santiago, de la Riva Onandía Susana, Echeveste José Ignacio, Muñoz Navas Miguel
Servicio de Digestivo, Clínica Universidad de Navarra, España.
Servicio de Digestivo, Clínica Universidad de Navarra.
Rev Esp Enferm Dig. 2017 Dec;109(12):863-864. doi: 10.17235/reed.2017.5060/2017.
Atezolizumab is an IgG1 isotype monoclonal antibody against the protein programmed cell death-ligand 1 (PD- L1). PD-L1 may be highly expressed in some tumors and is believed to inhibit immune cells that recognize and attack tumor cells. Inhibition of PD-L1 can remove its inhibitory effect and provoke an anti-tumor response. In October 2016, the Food and Drugs Administration (FDA) approved atezolizumab for the treatment of patients with metastatic non-small cell lung cancer after disease progression during or following platinum based chemotherapy. We present the case of a 43-year-old male with stage IV lung adenocarcinoma in progression, despite standard chemotherapy.
阿替利珠单抗是一种针对程序性细胞死亡配体1（PD-L1）蛋白的IgG1同型单克隆抗体。PD-L1可能在某些肿瘤中高表达，据信它会抑制识别并攻击肿瘤细胞的免疫细胞。抑制PD-L1可消除其抑制作用并引发抗肿瘤反应。2016年10月，美国食品药品监督管理局（FDA）批准阿替利珠单抗用于治疗在铂类化疗期间或之后病情进展的转移性非小细胞肺癌患者。我们报告了一例43岁男性患者的病例，尽管接受了标准化疗，其IV期肺腺癌仍在进展。
